DiaMedica reports Q2 2026 results, adds FGR enrollment and PE dose plans
DiaMedica completed its first fetal growth restriction cohort and detailed next steps for its preeclampsia program, while reporting $43.5 million in cash.
SEC filing
Latest
1 story